Literature DB >> 22949152

Double-hit diffuse large B-cell lymphoma.

Jonathan W Friedberg1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22949152     DOI： 10.1200/JCO.2012.43.5800

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  28 in total

1.  Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Authors:  Kieron Dunleavy; Michelle A Fanale; Jeremy S Abramson; Ariela Noy; Paolo Fabrizio Caimi; Stefania Pittaluga; Samir Parekh; Ann Lacasce; John W Hayslip; Deepa Jagadeesh; Sunil Nagpal; Mary Jo Lechowicz; Rakesh Gaur; Andrea Lucas; Christopher Melani; Mark Roschewski; Seth M Steinberg; Elaine S Jaffe; Brad Kahl; Jonathan W Friedberg; Richard F Little; Nancy L Bartlett; Wyndham H Wilson
Journal:  Lancet Haematol       Date:  2018-12       Impact factor: 18.959

2.  Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Authors:  Christopher D Carey; Daniel Gusenleitner; Bjoern Chapuy; Alexandra E Kovach; Michael J Kluk; Heather H Sun; Rachel E Crossland; Chris M Bacon; Vikki Rand; Paola Dal Cin; Long P Le; Donna Neuberg; Aliyah R Sohani; Margaret A Shipp; Stefano Monti; Scott J Rodig
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

3.  In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Authors:  Girija Dasmahapatra; Hiral Patel; Johnathan Friedberg; Steven N Quayle; Simon S Jones; Steven Grant
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

Review 4.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Authors:  Grzegorz S Nowakowski; Kristie A Blum; Brad S Kahl; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; David G Maloney; Laurie H Sehn; Michael E Williams; Wyndham H Wilson; John P Leonard; Sonali M Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-16       Impact factor: 13.506

Review 5.  Double-Hit Large B Cell Lymphoma.

Authors:  Yousef Khelfa; Yehuda Lebowicz; Muhammad Omer Jamil
Journal:  Curr Oncol Rep       Date:  2017-09-26       Impact factor: 5.075

6.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.

Authors:  Andrew D Zelenetz; Gilles Salles; Kylie D Mason; Carla Casulo; Steven Le Gouill; Laurie H Sehn; Herve Tilly; Guillaume Cartron; Martine E D Chamuleau; Andre Goy; Constantine S Tam; Pieternella J Lugtenburg; Adam M Petrich; Arijit Sinha; Divya Samineni; Sylvia Herter; Ellen Ingalla; Edith Szafer-Glusman; Christian Klein; Deepak Sampath; Martin Kornacker; Mehrdad Mobasher; Franck Morschhauser
Journal:  Blood       Date:  2019-03-08       Impact factor: 22.113

7.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 8.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

9.  Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Sam M Mbulaiteye; Lindsay M Morton; Joshua N Sampson; Ellen T Chang; Laura Costas; Silvia de Sanjosé; Tracy Lightfoot; Jennifer Kelly; Jonathan W Friedberg; Wendy Cozen; Rafael Marcos-Gragera; Susan L Slager; Brenda M Birmann; Dennis D Weisenburger
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

Review 10.  B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.

Authors:  Jean L Koff; Christopher R Flowers
Journal:  Expert Rev Hematol       Date:  2016-05-13       Impact factor: 2.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.